| DC47308 |
Lumasiran
Featured
|
Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1). |
|
| DC47310 |
Rovanersen
Featured
|
Rovanersen (WVE-120101) is an antisense oligonucleotide that can be used for huntington’s disease research. |
|
| DC47315 |
ML-SI3
Featured
|
ML-SI3 is a potent TRPML channel inhibitor with IC50s of 4.7 µM and 1.7 µM for TRPML1 and TRPML2, respectively. |
|
| DC47316 |
LOX-IN-3 Dihydrochloride
Featured
|
LOX-IN-3 Dihydrochloride is an orally active and selective lysyl oxidase (LOX) inhibitor. |
|
| DC47318 |
7,12-Dimethylbenz[a]anthracene (DMBA)
Featured
|
7,12-Dimethylbenz[a]anthracene (DMBA) is an immunosuppressor as well as a potent organ-specific carcinogen. |
|
| DC60155 |
Lu AF27139
Featured
|
Lu AF27139 is a novel rodent-active and CNS-penetrant P2X7 receptor antagonist. Lu AF27139 is highly selective and potent against rat, mouse, and human forms of the receptors. The rat pharmacokinetic profile is favorable with high oral bioavailability, modest clearance (0.79 L/(h kg)), and good CNS permeability. Importantly, Lu AF27139 was without effect in standard in vitro and in vivo toxicity studies. Lu AF27139 is a valuable tool for probing the role of the P2X7 receptor in rodent models of CNS diseases. |
|
| DC60156 |
Rasarfin
Featured
|
Rasarfin is a novel dual Ras and ARF6 inhibitor. Rasarfin blocks agonist-mediated internalization of AT1R and other GPCRs. Rasarfin also potently inhibits agonist-induced ERK1/2 signaling by GPCRs, and MAPK and Akt signaling by EGFR, as well as prevents cancer cell proliferation. In silico modeling and in vitro studies reveal a unique binding modality of Rasarfin within the SOS-binding domain of Ras.
Rasarfin is a novel dual Ras and ARF6 inhibitor. Rasarfin blocks agonist-mediated internalization of AT1R and other GPCRs. Rasarfin also potently inhibits agonist-induced ERK1/2 signaling by GPCRs, and MAPK and Akt signaling by EGFR, as well as prevents cancer cell proliferation. In silico modeling and in vitro studies reveal a unique binding modality of Rasarfin within the SOS-binding domain of Ras.
|
|
| DC60157 |
KYN101
Featured
|
KYN-101 is a novel potent and selective inhibitor of aryl hydrocarbon receptor (AHR) (IC50 of 22 nM in the human HepG2 DRE-luciferase reporter assay and 23 nM in the murine Hepa1 Cyp-luc assay). |
|
| DC60158 |
K-975
Featured
|
K-975 is a first-in-class TEAD inhibitor, directly inhibiting YAP/TAZ-TEAD protein-protein interaction and showing a potent anti-tumor effect in malignant pleural mesothelioma. K-975 was covalently bound to an internal cysteine residue located in the palm |
|
| DC60159 |
Azo-Resveratrol
Featured
|
Azo-Resveratrol is an analog of Resveratrol used as a potent tyrosinase inhibitor. |
|
| DC60160 |
Homo-VK-II-36
Featured
|
Homo-VK-II-36 is a carvedilol analogue. It acts by inhibiting store-overload-induced calcium release (SOICR) through the RyR2 channel. |
|
| DC60161 |
NSC2805
Featured
|
NSC-2805 is a WWP2 ubiquitin ligase inhibitor. |
|
| DC60162 |
GPR52-IN-43(CAY10786)
Featured
|
GPR52-IN-43(CAY10786) is a novel GPR52 antagonist, reducing mHTT levels by targeting GPR52 and promoting survival of mouse primary striatal neurons, and also reducing HD-related phenotypes in HdhQ140. |
|
| DC60163 |
FPPS-IN-11
Featured
|
|
|
| DC60165 |
DoPAT
Featured
|
|
|
| DC60166 |
Benzenecarbodithioicacid, phenylmethyl ester
Featured
|
|
|
| DC60167 |
Benzene, 1-[(1R)-1-(bromomethoxy)ethyl]-3,5-bis(trifluoromethyl)-
Featured
|
|
|
| DC60168 |
ethyl 2-ethoxycarbothioylsulfanylpropanoate
Featured
|
|
|
| DC60169 |
2,3,5,6-tetrahydropentalen-1(4H)-one
Featured
|
|
|
| DC60170 |
Propanoic acid, 3-[[[(phenylmethyl)thio]thioxomethyl]thio]-
Featured
|
|
|
| DC60171 |
ML353 (VU0478006)
Featured
|
ML353 (VU0478006) is a ovel Silent Allosteric Modulator (SAM) of the Metabotropic Glutamate Receptor 5. |
|
| DC60172 |
SY292470
Featured
|
|
|
| DC60173 |
BR-103354
Featured
|
BR103354 is a novel fibroblast activation protein (FAP) inhibitor with anti-diabetic and anti-steatotic effects. |
|
| DC60174 |
CAY10526
Featured
|
CAY10526 is a selective inhibitor of mPGES-1. It also acts as an inhibitor of the NF-κB signaling pathway. |
|
| DC60175 |
VK-28
Featured
|
|
|
| DC58000 |
4'-fluorouridine (4'-FlU, EIDD-2749)
Featured
|
4'-fluorouridine (4'-FlU, EIDD-2749) is a ribonucleoside analog that inhibits respiratory syncytial virus (RSV), related RNA viruses, and SARS-CoV-2 with high selectivity index (EC50/CC50 of ≥1877) in cells and human airway epithelia organoids. 4'-FlU induces a delayed stalling of RSV and SARS-CoV-2 RdRP (RNA-dependent RNA polymerase). |
|
| DC60176 |
M1001
Featured
|
M1001 is a novel allosteric agonist of hypoxia-inducible factor-2α subunit (hif-2α), significantly displacing pocket residue y281 |
|
| DC60177 |
Heparan N-sulfate
Featured
|
Heparan Sulfate is a complex and linear polysaccharide, exists as part of glycoproteins named heparan sulfate proteoglycans, which are expressed abundantly on the cell surface and in the extracellular matrix. |
|
| DC60178 |
Abatacept
Featured
|
|
|
| DC60179 |
Tuspetinib(HM43239)
Featured
|
HM43239 is an orally active small molecule inhibitor of FLT3 that selectively inhibits not only FLT3 wild type, ITD mutants or TKD mutations, but also FLT3 ITD/TKD double mutations. HM43239 directly inhibits the kinase activity of FLT3 as a reversible Type I inhibitor and effectively modulates downstream p-STAT5 and p-ERK. HM43239 also demonstrated inhibition of SYK, JAK1/2 and TAK1, known to be involved in tumor cell proliferation and/or differentiation HM43239 monotherapy induced dose-dependent regression of tumor growth in FLT3 wild-type and FLT3 mutated leukemia cancer cell line. |
|
